TRIM37‐Mediated Ubiquitination and Degradation of KMT2D Activates JAK2‐STAT3 Signaling to Promote Diffuse Large B‐Cell Lymphoma Progression
Hematological Oncology · 2026
DOI: 10.1002/hon.70191 ↗At a glance
Journal article in Hematological Oncology, 2026. Written by Yongcheng Sun and 9 co-authors. Institution: Department of Haematology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. Major MEDLINE topics: Lymphoma, Large B-Cell, Diffuse, STAT3 Transcription Factor, Janus Kinase 2, Ubiquitin-Protein Ligases. Cited 1 times so far (Crossref); 29 references. Funded by: National Natural Science Foundation of China.
Abstract (original language)
Diffuse large B‐cell lymphoma (DLBCL) is the most common and clinically aggressive subtype of non‐Hodgkin lymphoma, yet key molecular drivers remain incompletely defined. Here, we identify the tripartite motif E3 ligase TRIM37 as a disease‐relevant oncogenic factor in DLBCL. TRIM37 was markedly upregulated in patient specimens and cell lines, and high expression correlated with poor prognosis. Loss‐of‐function studies showed that TRIM37 silencing suppressed proliferation and clonogenicity, triggered apoptosis, and restrained tumor growth in vivo. Mechanistically, TRIM37 promoted ubiquitin‐proteasome degradation of the enhancer‐associated histone methyltransferase KMT2D, reducing H3K4me1 deposition at the SOCS3 regulatory region, repressing SOCS3, and thereby sustaining JAK2‐STAT3 phosphorylation. Rescue experiments supported causality: co‐silencing KMT2D or enforcing TRIM37 expression reversed these effects, while JAK2 inhibitor treatment reproduced the impact of TRIM37 loss. Collectively, these findings show that TRIM37 drives DLBCL progression by destabilizing KMT2D to disable SOCS3‐mediated negative feedback on JAK2‐STAT3 and highlight TRIM37 as a potential therapeutic target.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Haematology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
- Department of Scientific Research, Ningbo Medical Center Lihuili Hospital, Ningbo, China.
ORCID profiles: Aibin Liang
Funding
- National Natural Science Foundation of China
Cite
APA
Sun, Y., Xiu, B., Zhou, M., Yang, S., Xu, Z., Wang, Z., Zhang, P., Sheng, L., Ouyang, G., & Liang, A. (2026). TRIM37‐Mediated Ubiquitination and Degradation of KMT2D Activates JAK2‐STAT3 Signaling to Promote Diffuse Large B‐Cell Lymphoma Progression. Hematological Oncology. https://doi.org/10.1002/hon.70191
Vancouver
Sun Y, Xiu B, Zhou M, Yang S, Xu Z, Wang Z, et al. TRIM37‐Mediated Ubiquitination and Degradation of KMT2D Activates JAK2‐STAT3 Signaling to Promote Diffuse Large B‐Cell Lymphoma Progression. Hematological Oncology. 2026. doi:10.1002/hon.70191
BibTeX
@article{Sun2026,
author = {Sun, Yongcheng and Xiu, Bing and Zhou, Miao and Yang, Shujun and Xu, Zhijuan and Wang, Zanzan and Zhang, Ping and Sheng, Lixia and Ouyang, Guifang and Liang, Aibin},
title = {TRIM37‐Mediated Ubiquitination and Degradation of KMT2D Activates JAK2‐STAT3 Signaling to Promote Diffuse Large B‐Cell Lymphoma Progression},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70191}
}
EUVIMED